Design Therapeutics, Inc.

DSGN

US25056L1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
4.05 ^USD	+2.79%		-7.11%	+52.83%

05-08	Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	MT

Design Therapeutics, Inc. Appoints Elizabeth Gordon as Senior Vice President of Regulatory Affairs

August 09, 2021 at 09:05 pm

Design Therapeutics, Inc. announced the Leadership Team Strengthened with Appointment of Elizabeth Gordon, Ph.D., as Senior Vice President of Regulatory Affairs.

Latest news about Design Therapeutics, Inc.

Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	05-07	MT
Sector Update: Health Care Stocks Ease Late Afternoon	03-20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	03-20	MT
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	03-20	MT
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
North American Morning Briefing : Stock Futures -2-	03-19	DJ
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from NASDAQ Biotechnology Index	12-15	CI
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk	11-14	MT
Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating	11-14	MT
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Insider Buy: Design Therapeutics	31/08/23	MT
Design Therapeutics, Inc. Announces Principal Financial Officer Changes	25/08/23	CI
Design Therapeutics, Inc. Announces CEO Changes	25/08/23	CI
Design Therapeutics, Inc. Announces Management Changes	25/08/23	CI
North American Morning Briefing : China Trouble Hits Sentiment	18/08/23	DJ
North American Morning Briefing : Stock Futures -2-	16/08/23	DJ
Financial Sector Woes, Lackluster Chinese Data Weigh on US Equity Markets	15/08/23	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	15/08/23	MT
Sector Update: Health Care Stocks Slip Pre-Bell Tuesday	15/08/23	MT
Sentiment Subdued After Downbeat China Data, Pushing US Equity Futures Lower Pre-Bell	15/08/23	MT
Sector Update: Health Care	15/08/23	MT
SVB Downgrades Design Therapeutics to Market Perform From Outperform, Cuts Price Target to $6 From $22	15/08/23	MT
Top Premarket Decliners	15/08/23	MT

Chart Design Therapeutics, Inc.

Duration

Period

More charts

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Sector

Biotechnology & Medical Research

Calendar

13/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.05 USD

Average target price

6.667 USD

Spread / Average Target

+64.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DESIGN THERAPEUTICS, INC.	+52.83%	223M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B

Other Biotechnology & Medical Research